5848-04-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-fluorophenyl)-1H-pyrazol-5-amine is used as a pharmaceutical intermediate for the synthesis of various drugs. Its aromatic and amine functional groups contribute to the development of new therapeutic agents, making it a valuable component in medicinal chemistry.
Used in Chemical Research:
In the chemical industry, 4-(4-fluorophenyl)-1H-pyrazol-5-amine serves as a subject of research for the exploration of new chemical reactions and the creation of novel compounds. Its unique structure and functional groups provide a foundation for the advancement of chemical science and technology.
Used in Drug Development:
4-(4-fluorophenyl)-1H-pyrazol-5-amine is utilized in drug development for the creation of new pharmaceuticals. Its potential applications in the synthesis of drugs highlight its importance in the discovery and production of innovative medications to address various health conditions.

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 
• 398-42-5 2-formyl-2-(4-fluorophenyl) acetonitrile 

Downstream Products

• 1448466-49-6 1,3-dihydro-8-(4-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
• 1448466-65-6 8-(4-fluorophenyl)-2-thioxo-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one 

Relevant academic research and scientific papers

Development of Pyrazolopyrimidine Anti- Wolbachia Agents for the Treatment of Filariasis

Anti-Wolbachia therapy has been identified as a viable treatment for combating filarial diseases. Phenotypic screening revealed a series of pyrazolopyrimidine hits with potent anti-Wolbachia activity. This paper focuses on the exploration of the SAR for this chemotype, with improvement of metabolic stability and solubility profiles using medicinal chemistry approaches. Organic synthesis has enabled functionalization of the pyrazolopyrimidine core at multiple positions, generating a library of compounds of which many analogues possess nanomolar activity against Wolbachia in vitro with improved DMPK parameters. A lead compound, 15f, was selected for in vivo pharmacokinetics (PK) profiling in mice. The combination of potent anti-Wolbachia activity in two in vitro assessments plus the exceptional oral PK profiles in mice puts this lead compound in a strong position for in vivo proof-of-concept pharmacodynamics studies and demonstrates the strong potential for further optimization and development of this series for treatment of filariasis in the future.

3-amino- and 5-aminopyrazoles with anticonvulsant activity

New 3-amino- and 5-aminopyrazoles were synthesised. 3-Aminopyrazoles exert a strong anticonvulsant effect. 4-Chlorophenyl-3-(morpholin-4-yl)-1H- pyrazole 2 distinctively blocks sodium channels and is strongly effective in the Maximal Electroshock Seizure